Cancer Advance
Date: Location: Cost:
April 12 - 13, 2018 Harvard Medical School - Joseph B. Martin Conference Center
77 Avenue Louis Pasteur
Boston, MA 02115

Starting at $1950


Dress Code:
Business Attire



2018 Keynote Speaker: Laurie Glimcher, President & CEO, Dana Farber Cancer Institute

Balancing Advances with Setbacks: Lessons Learned from 2017

Staying Bold in Clinical Innovation: Oncology Drug Development

Clearing Hurdles in Broader Routine use of Breakthrough Technologies

Novel Therapeutic Modalities

Drug Approval Trends & Predictions in The US Regulatory Landscape

Latest Developments in Combination Therapies

Demonstrating Value in Oncology Drug Pricing

Investor Perspectives on the Oncology Market 2018 & Beyond

Immuno-Oncology: Challenges & Opportunities

Driving Innovation & Mitigating Risk

CAR T Cell Therapy: Breaking New Ground

Oncology 2018: Trends to Watch



Time Agenda
7:15-8:15 am

Registration and Networking Breakfast

8:15-8:30 am

Welcome and Opening Remarks
Giulio Draetta
VP, Therapeutics Discovery, MD Anderson Cancer Center; John HaurumCEO, F-Star Biotechnology; Henning SteinhagenEVP, Drug Discovery & Development, Aptuit; Bob OliverPresident & CEO, Otsuka Pharmaceuticals; Maria WhitmanManaging Principal, ZS Associates

8:30-9:00 am

Oncology 2017: Trends to Watch
Denise FaustmanDirector, Immunobiology, Massachusetts General Hospital; John HohnekerEVP & Head, R&D, FORMA Therapeutics; Bob OliverPresident & CEO, Otsuka Pharmaceuticals; James OlivieroPresident & CEO, Checkpoint Therapeutics; Maria WhitmanManaging Partner, ZS Associates
Moderator: Robert ForresterPresident & CEO, Verastem

9:00-9:30 am

Financing Innovation in the Oncology Market
Susan Graf, CBO, Epizyme; John HaurumCEO, F-Star Biotechnology; Martin LehrPresident & CBO, Context Therapeutics; Chris LeMastersEVP & CBO, Mirati Therapeutics
Moderator: Pablo CagnoniPresident & CEO, Tizona Therapeutics

9:30-10:00 am

Ensuring Transparency and Drug Value
Constantine ChinoporosCBO, Boston Pharmaceuticals; Marcia FournierFounder & CEO, Bioarray Genetics; Fatima ScipionePatient Advocacy, Takeda
Moderator: Jim CocciaVP, US Market Access, Oncology, Takeda

10:00-10:30 am

Networking Break

10:30-11:00 am

Novel Clinical Trial Design: Implementing Biomarkers and Diagnostics
Peter Blume-JensenCSO, XTuit; Giulio DraettaVP, Therapeutics Discovery, MD Anderson Cancer CenterOliver RosenCMO, Deciphera; Peter SmithCSO, H3 Biomedicine; Vivek VishnudasChief Technology Officer, BERG
Moderator: Edward GarmeyCMO, Bicycle Therapeutics

11:00-11:30 am

Leveraging Liquid Biopsies and New Technologies
Paul Beresford
CBO, Biodesix; Richard Lanman, CMO, Guardant Health; Jimmy LinCSO, Oncology, Natera; Jamie PlattDirector, US Commercial Lab Operations, Inivata
Moderator: George Demetri, SVP, Experimental Therapeutics, Dana Farber Cancer Institute

11:30-12:00 pm

Innovative Deal Structures in Oncology
Andrew CurtisHead, Strategy, Affimed Therapeutics AG; John DeYoungVP, WWBD, Pfizer; Shalabh GuptaPresident & CEO, Globavir Biosciences; Robert RadinskyVP, Oncology Scientific Innovation, Janssen Research & Development; Guillaume VignonHead, Immuno-Oncology Licensing & BD, Merck KGaA
Moderator: Bob SilvermanHead, Externalized Drug Discovery Partnering, Roche

12:00-1:00 pm

Networking Lunch 

1:00-1:30 pm

Maximizing Research Collaborations and Tech Transfer
Anne DeconinckExecutive Director, MIT Koch Institute; Philip GotwalsExecutive Director, Oncology Research, Novartis; Daniel O'ConnorPresident & CEO, Advaxis; Gary SclarVP, Innovations, Dana Farber Cancer Institute; Robert SpiegelCMO, PTC Therapeutics
Moderator: Joern-Peter HalleSVP, Head, External Innovation, EMD Serono

1:30-2:00 pm

Commercialization and Manufacturing: Strategies for Success
Art FratamicoCBO, Galera Therapeutics; Dinesh PurandareSVP, Global Oncology, Radius Health; Cynthia SchwalmEVP & President, North American Commercial Operations, IPSEN; Mallik Sundaram, President & CEO, Mitra Biotech; Alan WrightChief Medical Officer, Roche Diagnostics
Moderator: Pascal TouchonSVP Global Head, Strategy & BD, Novartis Oncology

2:00-2:30 pm

Immuno-Oncology Trends & Challenges
Sudhir AgrawalPresident, Research, Idera Pharmaceuticals; Chip ClarkPresident & CEO, Genocea Biosciences; Pamela Contag, CEO, ConcentRx Inc.; Björn FrendéusCSO, BioInvent; Kristine SwiderekCSO, OncoResponse
Moderator: Jonathan PachterCSO, Verastem

2:30-3:00 pm

Networking Break

3:00-3:30 pm

Advances in Combination Therapy
Errik AndersonCo-Founder, President & COOCompass Therapeutics; Arthur KriegFounder & CEO, Checkmate Pharmaceuticals; Ramesh KumarPresident & CEO, Onconova; Upendra MarathiPresident & CEO, 7 Hills Pharma
Moderator: Ferran PratVP, Strategic Industry Ventures, MD Anderson Cancer Center

3:30-4:00 pm

Partnering and M&A Outlook
Diala EzzeddineCEO, Xios Therapeutics; David GiljohannCEO, Exicure; Matt Roden, Head, Strategic Corporate Development, Bristol-Myers Squibb; Henning SteinhagenEVP, Discovery & Development, Aptuit
Moderator: Justin RenzEVP, CFO, & Treasurer, Karyopharm

4:00-4:30 pm

The Next 10 Years: Predictions and Wishes
Andrew AllenPresident & CEO, Gritstone Oncology; Robert BazemorePresident & CEO, Epizyme; Michele ClearyCEO, The Mark Foundation; JC Gutierrez-RamosCEO, Synlogic Therapeutics; Markus ThuneckeSenior Partner, Catenion
Moderator: Tim Clackson, CSO & President, R&D, ARIAD

4:30-4:45 pm

Presentation of the Oncology Innovation of the Year Award

4:45-6:00 pm

Cocktails and Hors d'oeuvres

Premier Sponsors: (see all sponsors)